A. Santhanagopal

Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates

K. Lasseter, A. Denker, A. Daifotis, 2005, Clinical drug investigation.

Epidermal growth factor stimulates proton efflux from chondrocytic cells

S. Dixon, S. Bernier, Amiesha S Panchal, 2002, Journal of cellular physiology.

Calcitonin (CT) Rapidly Increases Na+/H+ Exchange and Metabolic Acid Production: Effects Mediated Selectively by the C1a CT Receptor Isoform.

R. Baron, S. Dixon, W. Horne, 2001, Endocrinology.

The Calcitonin Receptor Stimulates Shc Tyrosine Phosphorylation and Erk1/2 Activation

R. Baron, S. Dixon, J. David, 1998, The Journal of Biological Chemistry.

202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer

B. González-Farré, T. Pascual, J. Guerra, 2022, Annals of Oncology.

Insulin-like growth factor I rapidly enhances acid efflux from osteoblastic cells.

S. Dixon, A. Santhanagopal, 1999, American journal of physiology. Endocrinology and metabolism.

Insulin-like growth factor I rapidly enhances acid efflux from osteoblastic cells.

S. Dixon, A. Santhanagopal, 1999, The American journal of physiology.

124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial

A. Prat, J. M. Ferrero-Cafiero, T. Pascual, 2023, ESMO Open.

Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study.

B. González-Farré, D. Sellami, J. M. Ferrero-Cafiero, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial

A. Prat, J. M. Ferrero-Cafiero, T. Pascual, 2023, ESMO Open.